CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced the appointment of Carol Nast as an independent director on the company’s Board, effective August 11, 2021.
August 16, 2021
· 5 min read